Grace Therapeutics (GRCE) News Today $3.29 -0.10 (-2.95%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period What is HC Wainwright's Forecast for GRCE FY2025 Earnings?February 22 at 2:59 AM | americanbankingnews.comGRCE: STRIVE-ON Results ReportedFebruary 21 at 7:32 PM | finance.yahoo.comGrace Therapeutics (NASDAQ:GRCE) Given Buy Rating at HC WainwrightFebruary 20 at 2:31 AM | americanbankingnews.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | markets.businessinsider.comGrace Therapeutics reports Q3 EPS (36c), consensus (46c)February 13, 2025 | markets.businessinsider.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | globenewswire.comGrace Therapeutics secures $15m for GTx-104 pre-commercial developmentFebruary 11, 2025 | finance.yahoo.comGrace Therapeutics price target raised to $11 from $8 at Craig-HallumFebruary 11, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for Grace Therapeutics (GRCE)February 11, 2025 | markets.businessinsider.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAHFebruary 10, 2025 | finanznachrichten.deGrace Therapeutics reports positive Phase 3 trial results for GTx-104February 10, 2025 | msn.comGrace Therapeutics secures up to $30 million financingFebruary 10, 2025 | msn.comGrace Therapeutics announces private placement financing of up to $30MFebruary 10, 2025 | markets.businessinsider.comGrace Therapeutics announces results from Phase 3 STRIVE-ON trialFebruary 10, 2025 | markets.businessinsider.comGrace Therapeutics Announces Private Placement Financing of up to $30 MillionFebruary 10, 2025 | globenewswire.comGrace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAHFebruary 10, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)January 30, 2025 | markets.businessinsider.com3 US Penny Stocks With Market Cap Under $70MJanuary 23, 2025 | finance.yahoo.comGrace Therapeutics Inc Ordinary SharesJanuary 10, 2025 | morningstar.com Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address GRCE Media Mentions By Week GRCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GRCE News Sentiment▼0.910.60▲Average Medical News Sentiment GRCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GRCE Articles This Week▼73▲GRCE Articles Average Week Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Seres Therapeutics News Sagimet Biosciences News BioXcel Therapeutics News Puma Biotechnology News Sutro Biopharma News Nuvectis Pharma News Lexeo Therapeutics News Coherus BioSciences News Black Diamond Therapeutics News Telomir Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GRCE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
